Cellosaurus logo
expasy logo

Cellosaurus RIL175-R (CVCL_B7TN)

[Text version]
Cell line name RIL175-R
Accession CVCL_B7TN
Resource Identification Initiative To cite this cell line use: RIL175-R (RRID:CVCL_B7TN)
Comments Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53.
Selected for resistance to: ChEBI; CHEBI_50924; Sorafenib (Nexavar).
Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:5173; HRAS (Note=With p.Gly12Val).
Disease Hepatocellular carcinoma of the mouse (NCIt: C38756)
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Breed/subspecies: C57BL/6.
Hierarchy Parent: CVCL_B7TK (RIL-175)
Category Cancer cell line
Publications

DOI=10.5282/edoc.26548
Messner M.
Sorafenib resistance of hepatocellular carcinoma: antibiotics second- line to sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption.
Thesis PhD (2020); Ludwig Maximilians University of Munich; Munich; Germany

PubMed=32652772; DOI=10.1096/fj.202001128R
Messner M., Schmitt S., Ardelt M.A., Frohlich T., Muller M., Pein H., Huber-Cantonati P., Ortler C., Koenig L.M., Zobel L., Koeberle A., Arnold G.J., Rothenfusser S., Kiemer A.K., Gerbes A.L., Zischka H., Vollmar A.M., Pachmayr J.
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
FASEB J. 34:11860-11882(2020)

Cross-references
Encyclopedic resources Wikidata; Q114312789
Entry history
Entry creation23-Jun-2022
Last entry update19-Dec-2024
Version number6